ALS — Real Improvements and Ongoing Support
Amyotrophic Lateral Sclerosis

Patient
Rebecca
Origin
Italy
Diagnosis
Amyotrophic Lateral Sclerosis (ALS), diagnosed July 2023
Treatment
December 2024
Author
Dr. Uladzislau Tsvirko
Patient Background
Rebecca, a woman from Italy, was diagnosed with amyotrophic lateral sclerosis (ALS) in July 2023. The initial symptoms presented in one lower limb and gradually progressed to involve the upper extremities and speech function, reflecting a typical pattern of disease progression. At the time of presentation at BioCells Medical, the condition was associated with increasing motor limitations, reduced muscle control, and emerging difficulties with speech clarity.
Treatment Protocol
- •Individualised regenerative medicine programme developed based on neurological status and clinical assessment
- •Cell-based therapeutic interventions targeting neuronal function and inflammatory modulation
- •All procedures performed under medical supervision within a structured clinical framework
- •Preparation for a second treatment cycle ongoing at the time of reporting
Reported Functional Changes
- •Improved mobility of the lower lip with clearer and more intelligible speech
- •Relaxation of previously clenched hands, with restored voluntary movement of index fingers
- •Increased overall strength — patient now transfers independently from bed to wheelchair and from wheelchair to car
- •Improved mobility in the initially affected leg, with restored movement in gluteal and thigh muscle groups
- •Greater physical confidence and improved daily functioning
Video Observation
Follow-up and Ongoing Monitoring
Rebecca remains under continued medical observation following the first treatment stage. Her family is currently preparing for the next treatment cycle, with the goal of further supporting neurological function, motor strength, and overall physical stability. Clinical monitoring and treatment planning continue to be guided by her individual response and functional dynamics.
Clinical Context
This clinical case highlights the potential functional changes that may be observed following a personalised regenerative medicine approach in a patient with ALS. At BioCells Medical, each treatment programme is tailored to the individual patient's condition, disease progression, and functional priorities, with close medical oversight throughout the process.
Note: All observations reported in this case are based on post-treatment follow-up communication with the patient's family and clinical team. Individual results vary. This case does not constitute a clinical trial and should not be interpreted as a guarantee of outcome.